|
1
|
Chen X and Song E: The theory of tumor
ecosystem. Cancer Commun (Lond). 42:587–608. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Swanton C, Bernard E, Abbosh C, Andre F,
Auwerx J, Balmain A, Bar-Sagi D, Bernards R, Bullman S, DeGregori
J, et al: Embracing cancer complexity: Hallmarks of systemic
disease. Cell. 187:1589–1616. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mancusi R and Monje M: The neuroscience of
cancer. Nature. 618:467–479. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Miller KD, Ostrom QT, Kruchko C, Patil N,
Tihan T, Cioffi G, Fuchs HE, Waite KA, Jemal A, Siegel RL, et al:
Brain and other central nervous system tumor statistics, 2021. CA
Cancer J Clin. 71:381–406. 2021.PubMed/NCBI
|
|
5
|
Weller M, Wen PY, Chang SM, Dirven L, Lim
M, Monje M and Reifenberger G: Glioma. Nat Rev Dis Primers.
10:332024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bagley SJ, Logun M, Fraietta JA, Wang X,
Desai AS, Bagley LJ, Nabavizadeh A, Jarocha D, Martins R, Maloney
E, et al: Intrathecal bivalent CAR T cells targeting EGFR and
IL13Ralpha2 in recurrent glioblastoma: Phase 1 trial interim
results. Nat Med. 30:1320–1329. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bagley SJ, Binder ZA, Lamrani L, Marinari
E, Desai AS, Nasrallah MP, Maloney E, Brem S, Lustig RA, Kurtz G,
et al: Repeated peripheral infusions of anti-EGFRvIII CAR T cells
in combination with pembrolizumab show no efficacy in glioblastoma:
A phase 1 trial. Nat Cancer. 5:517–531. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roth P, Gorlia T, Reijneveld JC, de Vos F,
Idbaih A, Frenel JS, Le Rhun E, Sepulveda JM, Perry J, Masucci GL,
et al: Marizomib for patients with newly diagnosed glioblastoma: A
randomized phase 3 trial. Neuro Oncol. 26:1670–1682. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sloan AE, Winter K, Gilbert MR, Aldape K,
Choi S, Wen PY, Butowski N, Iwamoto FM, Raval RR, Voloschin AD, et
al: RG-BN002: Phase I study of ipilimumab, nivolumab, and the
combination in patients with newly diagnosed glioblastoma. Neuro
Oncol. 26:1628–1637. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carpentier A, Stupp R, Sonabend AM, Dufour
H, Chinot O, Mathon B, Ducray F, Guyotat J, Baize N, Menei P, et
al: Repeated blood-brain barrier opening with a nine-emitter
implantable ultrasound device in combination with carboplatin in
recurrent glioblastoma: A phase I/II clinical trial. Nat Commun.
15:16502024. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Harwood DSL, Pedersen V, Bager NS, Schmidt
AY, Stannius TO, Areskeviciute A, Josefse K, Nørøxe DS, Scheie D,
Rostalski H, et al: Glioblastoma cells increase expression of notch
signaling and synaptic genes within infiltrated brain tissue. Nat
Commun. 15:78572024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Alhalabi OT, Fletcher MNC, Hielscher T,
Kessler T, Lokumcu T, Baumgartner U, Wittmann E, Schlue S, Göttmann
M, Rahman S, et al: A novel patient stratification strategy to
enhance the therapeutic efficacy of dasatinib in glioblastoma.
Neuro Oncol. 24:39–51. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hara T, Chanoch-Myers R, Mathewson ND,
Myskiw C, Atta L, Bussema L, Eichhorn SW, Greenwald AC, Kinker GS,
Rodman C, et al: Interactions between cancer cells and immune cells
drive transitions to mesenchymal-like states in glioblastoma.
Cancer Cell. 39:779–792.e11. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen L, Qi Q, Jiang X, Wu J, Li Y, Liu Z,
Cai Y, Ran H, Zhang S, Zhang C, et al: Phosphocreatine promotes
epigenetic reprogramming to facilitate glioblastoma growth through
stabilizing BRD2. Cancer Discov. 14:1547–1565. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kloosterman DJ, Erbani J, Boon M, Farber
M, Handgraaf SM, Ando-Kuri M, Sánchez-López E, Fontein B, Mertz M,
Nieuwland M, et al: Macrophage-mediated myelin recycling fuels
brain cancer malignancy. Cell. 187:5336–5356.e30. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Seguin C, Sporns O and Zalesky A: Brain
network communication: Concepts, models and applications. Nat Rev
Neurosci. 24:557–574. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bazinet V, Hansen JY and Misic B: Towards
a biologically annotated brain connectome. Nat Rev Neurosci.
24:747–760. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zamler DB and Hu J: Primitive
oligodendrocyte precursor cells are highly susceptible to
gliomagenic transformation. Cancer Res. 83:807–808. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu C, Sage JC, Miller MR, Verhaak RG,
Hippenmeyer S, Vogel H, Foreman O, Bronson RT, Nishiyama A, Luo L
and Zong H: Mosaic analysis with double markers reveals tumor cell
of origin in glioma. Cell. 146:209–221. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xiao Y and Czopka T:
Myelination-independent functions of oligodendrocyte precursor
cells in health and disease. Nat Neurosci. 26:1663–1669. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Buchanan J, da Costa NM and Cheadle L:
Emerging roles of oligodendrocyte precursor cells in neural circuit
development and remodeling. Trends Neurosci. 46:628–639. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li J, Miramontes TG, Czopka T and Monk KR:
Synaptic input and Ca2+ activity in zebrafish oligodendrocyte
precursor cells contribute to myelin sheath formation. Nat
Neurosci. 27:219–231. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Douw L, Breedt LC and Zimmermann MLM:
Cancer meets neuroscience: The association between glioma
occurrence and intrinsic brain features. Brain. 146:803–805. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Meyer J, Yu K, Luna-Figueroa E, Deneen B
and Noebels J: Glioblastoma disrupts cortical network activity at
multiple spatial and temporal scales. Nat Commun. 15:45032024.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Krishna S, Choudhury A, Keough MB, Seo K,
Ni L, Kakaizada S, Lee A, Aabedi A, Popova G, Lipkin B, et al:
Glioblastoma remodelling of human neural circuits decreases
survival. Nature. 617:599–607. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pan Y, Hysinger JD, Barron T, Schindler
NF, Cobb O, Guo X, Yalçın B, Anastasaki C, Mulinyawe SB, Ponnuswami
A, et al: NF1 mutation drives neuronal activity-dependent
initiation of optic glioma. Nature. 594:277–282. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Anastasaki C, Chatterjee J, Koleske JP,
Gao Y, Bozeman SL, Kernan CM, Marco Y, Marquez LI, Chen JK, Kelly
CE, et al: NF1 mutation-driven neuronal hyperexcitability sets a
threshold for tumorigenesis and therapeutic targeting of murine
optic glioma. Neuro Oncol. 26:1496–1508. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen P, Wang W, Liu R, Lyu J, Zhang L, Li
B, Qiu B, Tian A, Jiang W, Ying H, et al: Olfactory sensory
experience regulates gliomagenesis via neuronal IGF1. Nature.
606:550–556. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chatterjee J, Koleske JP, Chao A,
Sauerbeck AD, Chen JK, Qi X, Ouyang M, Boggs LG, Idate R, Marco Y,
et al: Brain injury drives optic glioma formation through
neuron-glia signaling. Acta Neuropathol Commun. 12:212024.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Romero-Garcia R, Mandal AS, Bethlehem RAI,
Crespo-Facorro B, Hart MG and Suckling J: Transcriptomic and
connectomic correlates of differential spatial patterning among
gliomas. Brain. 146:1200–1211. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hai L, Hoffmann DC, Wagener RJ, Azorin DD,
Hausmann D, Xie R, Huppertz MC, Hiblot J, Sievers P, Heuer S, et
al: A clinically applicable connectivity signature for glioblastoma
includes the tumor network driver CHI3L1. Nat Commun. 15:9682024.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Venkataramani V, Schneider M, Giordano FA,
Kuner T, Wick W, Herrlinger U and Winkler F: Disconnecting
multicellular networks in brain tumours. Nat Rev Cancer.
22:481–491. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Osswald M, Jung E, Sahm F, Solecki G,
Venkataramani V, Blaes J, Weil S, Horstmann H, Wiestler B, Syed M,
et al: Brain tumour cells interconnect to a functional and
resistant network. Nature. 528:93–98. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gillespie S and Monje M: An active role
for neurons in glioma progression: Making sense of Scherer's
structures. Neuro Oncol. 20:1292–1299. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Taylor KR, Barron T, Hui A, Spitzer A,
Yalcin B, Ivec AE, Geraghty AC, Hartmann GG, Arzt M, Gillespie SM,
et al: Glioma synapses recruit mechanisms of adaptive plasticity.
Nature. 623:366–374. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Taylor KR and Monje M:
Neuron-oligodendroglial interactions in health and malignant
disease. Nat Rev Neurosci. 24:733–746. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
de Ruiter Swain J, Michalopoulou E, Noch
EK, Lukey MJ and Van Aelst L: Metabolic partitioning in the brain
and its hijacking by glioblastoma. Genes Dev. 37:681–702. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Venkataramani V, Yang Y, Schubert MC,
Reyhan E, Tetzlaff SK, Wißmann N, Botz M, Soyka SJ, Beretta CA,
Pramatarov RL, et al: Glioblastoma hijacks neuronal mechanisms for
brain invasion. Cell. 185:2899–2917.e31. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sun Y, Wang X, Zhang DY, Zhang Z,
Bhattarai JP, Wang Y, Park KH, Dong W, Hung YF, Yang Q, et al:
Brain-wide neuronal circuit connectome of human glioblastoma.
Nature. 641:222–231. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hsieh AL, Ganesh S, Kula T, Irshad M,
Ferenczi EA, Wang W, Chen YC, Hu SH, Li Z, Joshi S, et al:
Widespread neuroanatomical integration and distinct
electrophysiological properties of glioma-innervating neurons. Proc
Natl Acad Sci USA. 121:e24174201212024. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Venkatesh HS, Morishita W, Geraghty AC,
Silverbush D, Gillespie SM, Arzt M, Tam LT, Espenel C, Ponnuswami
A, Ni L, et al: Electrical and synaptic integration of glioma into
neural circuits. Nature. 573:539–545. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Muller-Langle A, Lutz H, Hehlgans S, Rodel
F, Rau K and Laube B: NMDA Receptor-mediated signaling pathways
enhance radiation resistance, survival and migration in
glioblastoma Cells-A potential target for adjuvant radiotherapy.
Cancers (Basel). 11:5032019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Drexler R, Drinnenberg A, Gavish A, Yalcin
B, Shamardani K, Rogers A, Mancusi R, Taylor KR, Kim YS, Woo PJ, et
al: Cholinergic neuronal activity promotes diffuse midline glioma
growth through muscarinic signaling. Cell. 188:4640–4657.e30. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Stella M, Baiardi G, Pasquariello S, Sacco
F, Dellacasagrande I, Corsaro A, Mattioli F and Barbieri F:
Antitumor potential of antiepileptic drugs in human glioblastoma:
Pharmacological targets and clinical benefits. Biomedicines.
11:5822023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Badalotti R, Dalmolin M, Malafaia O, Ribas
Filho JM, Roesler R, Fernandes MAC and Isolan GR: Gene expression
of GABAA receptor subunits and association with patient survival in
glioma. Brain Sci. 14:2752024. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Barron T, Yalcin B, Su M, Byun YG, Gavish
A, Shamardani K, Xu H, Ni L, Soni N, Mehta V, et al: GABAergic
neuron-to-glioma synapses in diffuse midline gliomas. Nature.
639:1060–1068. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Duman C, Yaqubi K, Hoffmann A, Acikgoz AA,
Korshunov A, Bendszus M, Herold-Mende C, Liu HK and Alfonso J:
Acyl-CoA-Binding protein drives glioblastoma tumorigenesis by
sustaining fatty acid oxidation. Cell Metab. 30:274–289.e5. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Venkatesh HS, Johung TB, Caretti V, Noll
A, Tang Y, Nagaraja S, Gibson EM, Mount CW, Polepalli J, Mitra SS,
et al: Neuronal activity promotes glioma growth through
Neuroligin-3 secretion. Cell. 161:803–816. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Colucci-D'Amato L, Speranza L and
Volpicelli F: Neurotrophic factor BDNF, physiological functions and
therapeutic potential in depression, neurodegeneration and brain
cancer. Int J Mol Sci. 21:77772020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li J, Zhang B, Feng Z, An D, Zhou Z, Wan
C, Hu Y, Sun Y, Wang Y, Liu X, et al: Stabilization of KPNB1 by
deubiquitinase USP7 promotes glioblastoma progression through the
YBX1-NLGN3 axis. J Exp Clin Cancer Res. 43:282024. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Venkatesh HS, Tam LT, Woo PJ, Lennon J,
Nagaraja S, Gillespie SM, Ni J, Duveau DY, Morris PJ, Zhao JJ, et
al: Targeting neuronal activity-regulated neuroligin-3 dependency
in high-grade glioma. Nature. 549:533–537. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yun EJ, Kim D, Kim S, Hsieh JT and Baek
ST: Targeting Wnt/β-catenin-mediated upregulation of oncogenic
NLGN3 suppresses cancer stem cells in glioblastoma. Cell Death Dis.
14:4232023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Guo Z, An P and Hong X: has-miR-134-5p
inhibits the proliferation and migration of glioma cells by
regulating the BDNF/ERK signaling pathway. Aging (Albany NY).
16:6510–6520. 2024.PubMed/NCBI
|
|
54
|
Griffin M, Khan R, Basu S and Smith S: Ion
channels as therapeutic targets in high grade gliomas. Cancers
(Basel). 12:30682020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Elias AF, Lin BC and Piggott BJ: Ion
channels in gliomas-from molecular basis to treatment. Int J Mol
Sci. 24:25302023. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Sharma G, Braga CB, Chen KE, Jia X,
Ramanujam V, Collins BM, Rittner R and Mobli M: Structural basis
for the binding of the cancer targeting scorpion toxin, ClTx, to
the vascular endothelia growth factor receptor neuropilin-1. Curr
Res Struct Biol. 3:179–186. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Barish ME, Aftabizadeh M, Hibbard J,
Blanchard MS, Ostberg JR, Wagner JR, Manchanda M, Paul J, Stiller
T, Aguilar B, et al: Chlorotoxin-directed CAR T cell therapy for
recurrent glioblastoma: Interim clinical experience demonstrating
feasibility and safety. Cell Rep Med. 6:1023022025. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
D'Alessandro G, Grimaldi A, Chece G,
Porzia A, Esposito V, Santoro A, Salvati M, Mainiero F, Ragozzino
D, Di Angelantonio S, et al: KCa3.1 channel inhibition sensitizes
malignant gliomas to temozolomide treatment. Oncotarget.
7:30781–30796. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Dong W, Fekete A, Chen X, Liu H, Beilhartz
GL, Chen X, Bahrampour S, Xiong Y, Yang Q, Zhao H, et al: A
designer peptide against the EAG2-Kvβ2 potassium channel targets
the interaction of cancer cells and neurons to treat glioblastoma.
Nat Cancer. 4:1418–1436. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Han L, Zhou J, Li L, Wu X, Shi Y, Cui W,
Zhang S, Hu Q, Wang J, Bai H, et al: SLC1A5 enhances malignant
phenotypes through modulating ferroptosis status and immune
microenvironment in glioma. Cell Death Dis. 13:10712022. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Long PM, Moffett JR, Namboodiri AMA,
Viapiano MS, Lawler SE and Jaworski DM: N-acetylaspartate (NAA) and
N-acetylaspartylglutamate (NAAG) promote growth and inhibit
differentiation of glioma stem-like cells. J Biol Chem.
288:26188–26200. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Hausmann D, Hoffmann DC, Venkataramani V,
Jung E, Horschitz S, Tetzlaff SK, Jabali A, Hai L, Kessler T,
Azoŕin DD, et al: Autonomous rhythmic activity in glioma networks
drives brain tumour growth. Nature. 613:179–186. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Jung E, Alfonso J, Monyer H, Wick W and
Winkler F: Neuronal signatures in cancer. Int J Cancer.
147:3281–3291. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Watson DC, Bayik D, Storevik S, Moreino
SS, Sprowls SA, Han J, Augustsson MT, Lauko A, Sravya P, Røsland
GV, et al: GAP43-dependent mitochondria transfer from astrocytes
enhances glioblastoma tumorigenicity. Nat Cancer. 4:648–664. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Gritsenko PG, Atlasy N, Dieteren CEJ,
Navis AC, Venhuizen JH, Veelken C, Schubert D, Acker-Palmer A,
Westerman BA, Wurdinger T, et al: p120-catenin-dependent collective
brain infiltration by glioma cell networks. Nat Cell Biol.
22:97–107. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Jung E, Osswald M, Blaes J, Wiestler B,
Sahm F, Schmenger T, Solecki G, Deumelandt K, Kurz FT, Xie R, et
al: Tweety-homolog 1 drives brain colonization of gliomas. J
Neurosci. 37:6837–6850. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Joseph JV, Magaut CR, Storevik S, Geraldo
LH, Mathivet T, Latif MA, Rudewicz J, Guyon J, Gambaretti M, Haukas
F, et al: TGF-β promotes microtube formation in glioblastoma
through thrombospondin 1. Neuro Oncol. 24:541–53. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Becker KN and Eisenmann KM: New targets in
the glioblastoma tumor microtube multiverse: Emerging roles for the
TGF-β/TSP1 signaling axis. Neuro Oncol. 24:554–555. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Hatcher A, Yu K, Meyer J, Aiba I, Deneen B
and Noebels JL: Pathogenesis of peritumoral hyperexcitability in an
immunocompetent CRISPR-based glioblastoma model. J Clin Invest.
130:2286–2300. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Campbell SL, Robel S, Cuddapah VA, Robert
S, Buckingham SC, Kahle KT and Sontheimer H: GABAergic
disinhibition and impaired KCC2 cotransporter activity underlie
tumor-associated epilepsy. Glia. 63:23–36. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Yu K, Lin CJ, Hatcher A, Lozzi B, Kong K,
Huang-Hobbs E, Cheng YT, Beechar VB, Zhu W, Zhang Y, et al: PIK3CA
variants selectively initiate brain hyperactivity during
gliomagenesis. Nature. 578:166–171. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Tobochnik S, Dorotan MKC, Ghosh HS,
Lapinskas E, Vogelzang J, Reardon DA, Ligon KL, Bi WL, Smirnakis SM
and Lee JW: Glioma genetic profiles associated with
electrophysiologic hyperexcitability. Neuro Oncol. 26:323–334.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong
W, Yi M and Xiang B: Regulatory mechanisms of PD-1/PD-L1 in
cancers. Mol Cancer. 23:1082024. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Xie P, Yu M, Zhang B, Yu Q, Zhao Y, Wu M,
Jin L, Yan J, Zhou B, Liu S, et al: CRKL dictates anti-PD-1
resistance by mediating tumor-associated neutrophil infiltration in
hepatocellular carcinoma. J Hepatol. 81:93–107. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Liu Q, Guan Y and Li S: Programmed death
receptor (PD-)1/PD-ligand (L)1 in urological cancers: The
‘all-around warrior’ in immunotherapy. Mol Cancer. 23:1832024.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Li X, Liu Y, Gui J, Gan L and Xue J: Cell
identity and spatial distribution of PD-1/PD-L1 blockade
responders. Adv Sci (Weinh). 11:e24007022024. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Reardon DA, Brandes AA, Omuro A,
Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr
O, et al: Effect of nivolumab vs bevacizumab in patients with
recurrent glioblastoma: The CheckMate 143 phase 3 randomized
clinical trial. JAMA Oncol. 6:1003–1010. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Lin H, Liu C, Hu A, Zhang D, Yang H and
Mao Y: Understanding the immunosuppressive microenvironment of
glioma: Mechanistic insights and clinical perspectives. J Hematol
Oncol. 17:312024. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Nejo T, Krishna S, Yamamichi A,
Lakshmanachetty S, Jimenez C, Lee KY, Baker DL, Young JS, Chen T,
Phyu SSS, et al: Glioma-neuronal circuit remodeling induces
regional immunosuppression. Nat Commun. 16:47702025. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Gonzalez-Calvo I, Cizeron M, Bessereau JL
and Selimi F: Synapse formation and function across species:
Ancient roles for CCP, CUB, and TSP-1 structural domains. Front
Neurosci. 16:8664442022. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Liu Z, Wen J, Hu F, Wang J, Hu C and Zhang
W: Thrombospondin-1 induced programmed death-ligand 1-mediated
immunosuppression by activating the STAT3 pathway in osteosarcoma.
Cancer Sci. 113:432–445. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Guo X, Pan Y, Xiong M, Sanapala S,
Anastasaki C, Cobb O, Dahiya S and Gutmann DH: Midkine activation
of CD8+ T cells establishes a neuron-immune-cancer axis
responsible for low-grade glioma growth. Nat Commun. 11:21772020.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Guo X, Qiu W, Wang C, Qi Y, Li B, Wang S,
Zhao R, Cheng B, Han X, Du H, et al: Neuronal activity promotes
glioma progression by inducing Proneural-to-Mesenchymal transition
in glioma stem cells. Cancer Res. 84:372–387. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Guo X, Qiu W, Li B, Qi Y, Wang S, Zhao R,
Cheng B, Han X, Du H, Pan Z, et al: Hypoxia-induced neuronal
activity in glioma patients polarizes microglia by potentiating RNA
m6A demethylation. Clin Cancer Res. 30:1160–1174. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Chen HC, He P, McDonald M, Williamson MR,
Varadharajan S, Lozzi B, Woo J, Choi DJ, Sardar D, Huang-Hobbs E,
et al: Histone serotonylation regulates ependymoma tumorigenesis.
Nature. 632:903–910. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Drexler R, Khatri R, Sauvigny T, Mohme M,
Maire CL, Ryba A, Zghaibeh Y, Dührsen L, Salviano-Silva A, Lamszus
K, et al: A prognostic neural epigenetic signature in high-grade
glioma. Nat Med. 30:1622–1635. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Hasani F, Masrour M, Khamaki S, Jazi K,
Ghoodjani E and Teixeira AL: Brain-derived neurotrophic factor
(BDNF) as a potential biomarker in brain glioma: A systematic
review and Meta-Analysis. Brain Behav. 15:e702662025. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Li Y, Wang J, Song SR, Lv SQ, Qin JH and
Yu SC: Models for evaluating glioblastoma invasion along white
matter tracts. Trends Biotechnol. 42:293–309. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Wei Y, Li C, Cui Z, Mayrand RC, Zou J,
Wong ALKC, Sinha R, Matys T, Schönlieb CB and Price SJ: Structural
connectome quantifies tumour invasion and predicts survival in
glioblastoma patients. Brain. 146:1714–1727. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Salvalaggio A, Pini L, Gaiola M, Velco A,
Sansone G, Anglani M, Fekonja L, Chioffi F, Picht T, Thiebaut de
Schotten M, et al: White matter tract density index prediction
model of overall survival in glioblastoma. JAMA Neurol.
80:1222–1231. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Abhinav K, Yeh FC, Mansouri A, Zadeh G and
Fernandez-Miranda JC: High-definition fiber tractography for the
evaluation of perilesional white matter tracts in High-grade glioma
surgery. Neuro Oncol. 17:1199–1209. 2015.PubMed/NCBI
|
|
92
|
Mastall M, Roth P, Bink A, Fischer Maranta
A, Laubli H, Hottinger AF, Hundsberger T, Migliorini D, Ochsenbein
A, Seystahl K, et al: A phase Ib/II randomized, open-label drug
repurposing trial of glutamate signaling inhibitors in combination
with chemoradiotherapy in patients with newly diagnosed
glioblastoma: The GLUGLIO trial protocol. BMC Cancer. 24:822024.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Yamaguchi K, Kumakura S, Someya A, Iseki
M, Inada E and Nagaoka I: Anti-inflammatory actions of gabapentin
and pregabalin on the substance P-induced mitogen-activated protein
kinase activation in U373 MG human glioblastoma astrocytoma cells.
Mol Med Rep. 16:6109–6115. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Bernstock JD, Mehari M, E Gerstl JV,
Meredith DM, Valdes PA, Heesen P, Ambati VS, Krishna S, Chen JA,
Arora H, et al: Gabapentinoids confer survival benefit in human
glioblastoma. Nat Commun. 16:44832025. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Lan YL, Zou S, Wang W, Chen Q and Zhu Y:
Progress in cancer neuroscience. MedComm (2020). 4:e4312023.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Tobochnik S, Regan MS, Dorotan MKC, Reich
D, Lapinskas E, Hossain MA, Stopka S, Santagata S, Murphy MM,
Arnaout O, et al: Pilot trial of perampanel on peritumoral
hyperexcitability and clinical outcomes in newly diagnosed
high-grade glioma. medRxiv [Preprint]. Apr 18–2024.doi:
10.1101/2024.04.11.24305666. PubMed/NCBI
|
|
97
|
Friess D, Brauer S, Poysti A, Choudhury C
and Harris L: Tools to study neural and glioma stem cell
quiescence. Trends Neurosci. 47:736–748. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Picart T and Hervey-Jumper S: Central
nervous system regulation of diffuse glioma growth and invasion:
From single unit physiology to circuit remodeling. J Neurooncol.
169:1–10. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Read RD, Tapp ZM, Rajappa P and
Hambardzumyan D: Glioblastoma microenvironment-from biology to
therapy. Genes Dev. 38:360–379. 2024.PubMed/NCBI
|
|
100
|
Ng S, Duffau H and Herbet G: Perspectives
in human brain plasticity sparked by glioma invasion: From
intraoperative (re)mappings to neural reconfigurations. Neural
Regen Res. 19:947–948. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Wei J, Wang M, Li S, Han R, Xu W, Zhao A,
Yu Q, Li H, Li M and Chi G: Reprogramming of astrocytes and glioma
cells into neurons for central nervous system repair and
glioblastoma therapy. Biomed Pharmacother. 176:1168062024.
View Article : Google Scholar : PubMed/NCBI
|
